Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

ABSTRACT:

Purpose

Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.

Methods

CH-ACM-01 was an open-label trial (N = 155) and CHIASMA OPTIMAL was a double-blind placebo-controlled (DPC) trial (N = 56), both investigating OOC as maintenance therapy for patients with acromegaly who were biochemical responders receiving iSRLs.

Results

Baseline characteristics in both trials reflected those expected of patients with acromegaly responding to treatment and were similar between trials, despite differences in inclusion criteria. OOC demonstrated a consistent degree of biochemical response across trials, with 65% of patients in CH-ACM-01 maintaining res

SUBMITTER: Labadzhyan A 

PROVIDER: S-EPMC8550586 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature